Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.7101
+0.0101 (1.44%)
At close: Feb 13, 2026, 4:00 PM EST
0.7052
-0.0049 (-0.69%)
After-hours: Feb 13, 2026, 5:20 PM EST
Pasithea Therapeutics Employees
Pasithea Therapeutics had 4 employees as of December 31, 2024. The number of employees decreased by 4 or -50.00% compared to the previous year.
Employees
4
Change (1Y)
-4
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$3,373,619
Market Cap
16.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 4 | -4 | -50.00% | 4 | 0 |
| Dec 31, 2023 | 8 | -7 | -46.67% | 8 | 0 |
| Dec 31, 2022 | 15 | 10 | 200.00% | 15 | 0 |
| Dec 31, 2021 | 5 | 2 | 66.67% | 3 | 2 |
| Jun 30, 2021 | 3 | - | - | 1 | 2 |
| Mar 31, 2021 | 3 | - | - | 1 | 2 |
| Dec 31, 2020 | 3 | - | - | 1 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Lunai Bioworks | 29 |
| Citius Pharmaceuticals | 23 |
| Quantum BioPharma | 17 |
| FibroBiologics | 13 |
| VYNE Therapeutics | 13 |
| Iterum Therapeutics | 9 |
| Lexaria Bioscience | 7 |
KTTA News
- 4 weeks ago - Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients - GlobeNewsWire
- 5 months ago - Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients - GlobeNewsWire